Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

GSK shares surge as the drugmaker raises its 2031 sales target to over £40bn, boosts dividends, and announces a £2bn share buyback plan.

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, ...

GSK PLC closed 24.32% short of its 52-week high of £18.24, which the company achieved on May 16th.

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

On Monday, GSK plc (GSK) stock saw a decline, ending the day at $34.9 which represents a decrease of $-0.37 or -1.05% from the prior close of $35.27. The stock opened at $34.87 and touched a low of ...

GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 2025.

Bearish flow noted in GSK (GSK) Pharma with 1,131 puts trading, or 2x expected. Most active are Mar-25 33 puts and Jan-26 35 puts, with total volume in those strikes near 730 contracts. The Put/Call ...

British pharmaceutical group GSK on Wednesday reported a near halving of net profit in 2024 after settling hefty US lawsuits over its Zantac heartburn drug.

Final investment decisions had been made for the Tarbert Next (LON: NXT) Generation biopower station in Co Kerry and the ...